Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.…
Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access
Humacyte (NASDAQ: HUMA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 184 employees.
The shares were at 0.4454 USD on 20 November 2026, down 66.5% over 52 weeks. Its 52-week range is 0.3370 USD to 1.520 USD: the price is 70.7% below the high and 32.2% above the low.
Its market capitalisation is 123.73M USD.
Humacyte reports revenue up 36.5% year over year.
Its debt exceeds its cash by 2.66M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 1.642 USD is 268.6% above the current price. The next earnings report is expected on 25 March 2027.